Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis

American Journal of Gastroenterology

Volumn 97, Issue 12, 2002, Pages 2939-2941

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ACYLTRANSFERASE; BALSALAZIDE; MESALAZINE; OLSALAZINE; PRODRUG; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; SULFONAMIDE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EPIDERMOLYSIS; EPIGASTRIC PAIN; FEVER; FOLIC ACID DEFICIENCY; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LEUKOPENIA; LUNG DISEASE; MALE INFERTILITY; META ANALYSIS; NAUSEA; NEPHROTOXICITY; PANCREATITIS; PRIORITY JOURNAL; RASH; REMISSION; SIDE EFFECT; STATISTICAL ANALYSIS; STEVENS JOHNSON SYNDROME; STOMACH PH; SUSTAINED RELEASE PREPARATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; ULCERATIVE COLITIS; URINARY EXCRETION; VOMITING;

EID: 0036897124     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2002.07092.x     Document Type: Editorial

References (45)

1. Das KM, Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1976;1:406-25.
2. Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs 1991;41:647-64.
3. Ragunath K, Williams JG. Review article: Balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther 2001;15:1549-54.
4. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972;181:555-62.
5. Prakash A, Markham A. Oral delayed-release mesalazine: A review of its use in ulcerative colitis and Crohn's disease. Drugs 1999;57:383-408.
6. Clemett D, Markham A, Prolonged-release mesalazine: A review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 2000;59:929-56.
7. Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989;97:38-41.
8. Ireland A, Priddle JD, Jewell DP. Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. Clin Sci (Lond) 1990;78:105-11.
9. Goebell H, Klotz U, Nehlsen B, Layer P. Oroileal transit of slow release 5-aminosalicylic acid. Gut 1993;34:669-75.
10. Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995;108:1427-33.
11. Zhou SY, Fleisher D, Pao LH, et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999;27: 479-85.
12. Staerk Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31:1271-6.
13. Christensen LA, Fallingborg J, Jacobsen BA, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 1994;8:289-94.
14. Stretch GL, Campbell BJ, Dwarakanath AD, et al. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther 1996;10:941-7.
15. Karamanolis DG, Papatheodoridis GV, Xourgias V. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Eur J Gastroenterol Hepatol 1996;8:1083-8.
16. Sandborn WJ, Hanauer SB, Buch A. Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. Asacol and Colazal. Am J Gastroenterol 2002;97:S263.
17. Sandborn WJ, Hanauer SB. The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: A systematic review. Am J Gastroenterol 2002;97: S269.
18. Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5.
19. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983;28:833-42.
20. Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology 1988;95:975-81.
21. Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: A randomised double blind trial. Gut 1989;30:1354-61.
22. Brouillard M, Gheerbrant JD, Gheysens Y, et al. Chronic interstitial nephritis and mesalazine: 3 New cases? Gastroenterol Clin Biol 1998;22:724-6.
23. Calvino J, Romero R, Pintos E, et al. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol 1998;49:265-7.
24. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: Effects of drug treatment. Gut 1992;33:1348-52.
25. Schreiber S, Hamling J, Zehnter E, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997;40:761-6.
26. Fraser JS, Muller AF, Smith DJ, et al. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 2001;15: 1131-7.
27. Mahmud N, O'Toole D, O'Hare N, et al. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther 2002;16:207-15.
28. Hanauer SB, Verst-Brasch C, Regalli G. Renal safety of long-term mesalamine therapy in inflammatory bowel disease (IBD). Gastroenterology 1997;112:A991 (abstract).
29. Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 Pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996;10:949-56.
30. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.
31. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997;3:65-78.
32. Courtney MG, Nunes DP, Bergin CF, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992;339:1279-81.
33. Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998;114:15-22.
34. Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut 1992;33:252-5.
35. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:391-6.
36. Nilsson A, Danielsson A, Lofberg R, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: A multicenter study. Am J Gastroenterol 1995;90:381-7.
37. Rijk MC, van Lier HJ, van Tongeren JH. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: A prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group. Am J Gastroenterol 1992;87:438-42.
38. Levine DS, Riff DS, Pruitt R, et al. A randomized, doubleblind, dose-response comparison of balsalazide 6.75 g, balsalazide 2.25 g, and mesalamine 2.4 g in the treatment of active, mild to moderate ulcerative colitis. Am J Gastroenerol 2002;97:1398-1407.
39. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild to moderate ulcerative colitis. Am J Gastroenterol 2002;97:3078-86.
40. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001;49:783-9.
41. Green JR, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16:61-8.
42. Mansfield JC, Giaffer MH, Cann PA, et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002;16:69-77.
43. Green JR, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: A comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator Group. Aliment Pharmacol Ther 1998;12:1207-16.
44. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
45. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993;88:1188-97.